$RZRA · Rezera Inc.
Rezera Inc. (formerly NodThera Inc.) filed Amendment No. 1 to its S-1 for an IPO of 16,666,667 common shares at an expected $11.00–$13.00 per share, applying to list on Nasdaq under "RZRA." GSK affiliate Glaxo Group Limited has indicated interest in buying up to 2,083,333 shares (~$25.0M at the $12.00 midpoint), about 10% of post-offering shares. The company is a clinical-stage biotech developing oral NLRP3 inhibitors, with lead candidate ruvonoflast targeting peripheral artery disease (PAD).
- Offering of 16,666,667 shares at $11.00–$13.00 per share, with a 30-day underwriter option for 2,500,000 additional shares.
- GSK affiliate indicated interest in up to 2,083,333 shares (~$25.0M), roughly 10% of post-offering shares outstanding.
- Lead candidate ruvonoflast reduced hsCRP by 82% vs 37% placebo in a calorie-restricted high-cardiovascular-risk trial.
- RESOLVE-1 Phase 2 showed 56.4%–62.6% hsCRP reduction at week 4 across 150 mg QD/BID doses.
- Company plans to initiate a Phase 3 PAD trial in the first half of 2027.
Price data unavailable.
A clinical-stage biotech with a GSK-anchored ~10% indication of interest is bringing a novel oral NLRP3 inhibitor to public markets ahead of a pivotal Phase 3 trial.
Rezera joins a wave of inflammation-targeting cardiovascular biotechs, positioning ruvonoflast against validated anti-inflammatory approaches (canakinumab, colchicine) with an oral, brain-penetrant profile.
No clinical trials of ruvonoflast have been conducted in PAD patients; all supporting data come from other indications. GSK's interest is non-binding and may not result in any purchase.